This category covers biotechnology and pharmaceutical companies developing synthetic biology approaches for Alzheimer's disease beyond traditional PROTACs and molecular glues. These companies leverage engineered biological systems including engineered proteins, engineered enzymes, gene circuits, metabolic engineering, biosensors, and cell engineering to develop novel disease-modifying therapies.
| Technology | Description | Application in AD |
|---|---|---|
| Engineered Proteins | Modified therapeutic proteins with enhanced properties | Improved brain penetration, target specificity |
| Engineered Enzymes | Optimized enzymes for protein clearance | Amyloid-degrading enzymes, aggregation inhibitors |
| Gene Circuits | Synthetic genetic circuits for controlled expression | Regulated therapeutic protein production |
| Metabolic Engineering | Modified metabolic pathways for neuroprotection | Bioenergetic support, metabolite production |
| Biosensors | Engineered detection systems for biomarkers | Early diagnosis, treatment monitoring |
| Cell Engineering | Modified cells for therapeutic delivery | Engineered probiotics, cellular therapeutics |
Headquarters: Boston, Massachusetts
Founded: 2008
NASDAQ: DNA
Ginkgo Bioworks is a leading synthetic biology company with a platform for organism engineering that combines software, hardware, and biological innovation. Their foundry capabilities include automated strain design, enzyme engineering, biosensor development, and therapeutic protein production[1].
Alzheimer's Disease Applications:
See Also: Ginkgo Bioworks[2]
Headquarters: South San Francisco, California
Founded: 2013
NASDAQ: TWST
Twist Bioscience is a leading DNA synthesis company providing synthetic genes, gene fragments, and oligo pools for drug discovery and development[3].
Alzheimer's Disease Applications:
See Also: Twist Bioscience
Headquarters: Redwood City, California
Founded: 2007
NASDAQ: CDXS
Codexis is an enzyme engineering company that develops and manufactures high-performance enzymes for pharmaceutical manufacturing and biotherapeutics[4].
Alzheimer's Disease Applications:
See Also: Codexis
Headquarters: Salt Lake City, Utah
Founded: 2013
NASDAQ: RXRX
Recursion Pharmaceuticals combines experimental biology and computational approaches to drug discovery using a high-throughput platform[5].
Alzheimer's Disease Applications:
See Also: Recursion Pharmaceuticals
Headquarters: Seattle, Washington
Founded: 2008
Private
Arzeda uses computational protein design to create novel enzymes with improved catalytic properties and stability[6].
Alzheimer's Disease Applications:
See Also: Arzeda
Headquarters: San Francisco, California
Founded: 2014
Private
Molekule is focused on developing engineered enzyme therapeutics for precision degradation of disease-causing proteins[7].
Alzheimer's Disease Applications:
See Also: Molekule
| Company | Focus | Stage |
|---|---|---|
| Molekule | Engineered amyloid-degrading enzymes | Preclinical |
| Codexis | Enzyme therapeutics | Preclinical |
| Arzeda | Computational enzyme design | Discovery |
| Company | Focus | Stage |
|---|---|---|
| Ginkgo Bioworks | Engineered cell therapies | Discovery |
| Recursion | Phenotypic screening platform | Phase 1/2 |
| Company | Focus | Stage |
|---|---|---|
| Ginkgo Bioworks | Biomarker biosensors | Discovery |
| Twist Bioscience | Diagnostic detection | Development |
| Company | Platform | Key Advantage | AD Focus |
|---|---|---|---|
| Ginkgo Bioworks | Foundry automation | Scale, speed | Disease modeling, screening |
| Twist Bioscience | DNA synthesis | High-throughput | Antibody discovery |
| Codexis | Enzyme engineering | Catalytic efficiency | Protein clearance |
| Recursion | Phenotypic screening | Phenotypic insights | Target identification |
| Arzeda | Computational design | Novel enzymes | Enzyme therapeutics |
| Molekule | Precision degradation | Specificity | Protein clearance |
Engineered proteins offer advantages over small molecules including:
Enzyme-based approaches for AD include:
Cell-based therapies leverage: